Insider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) Insider Sells $204,732.90 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) insider John J. Boniface sold 21,438 shares of the stock in a transaction on Tuesday, March 26th. The stock was sold at an average price of $9.55, for a total value of $204,732.90. Following the transaction, the insider now directly owns 143,524 shares in the company, valued at approximately $1,370,654.20. The transaction was disclosed in a filing with the SEC, which is available at this link.

Sera Prognostics Price Performance

SERA opened at $9.10 on Friday. Sera Prognostics, Inc. has a 12-month low of $1.52 and a 12-month high of $10.44. The business’s fifty day simple moving average is $8.47 and its 200-day simple moving average is $5.03.

Institutional Investors Weigh In On Sera Prognostics

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Sera Prognostics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 909,502 shares of the company’s stock valued at $5,439,000 after purchasing an additional 122,710 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new stake in Sera Prognostics during the fourth quarter valued at about $909,000. Mission Creek Capital Partners Inc. bought a new stake in Sera Prognostics during the fourth quarter valued at about $195,000. StepStone Group LP bought a new stake in Sera Prognostics during the fourth quarter valued at about $61,000. Finally, Northern Trust Corp boosted its position in Sera Prognostics by 20.8% during the fourth quarter. Northern Trust Corp now owns 32,842 shares of the company’s stock valued at $196,000 after purchasing an additional 5,651 shares in the last quarter. Institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression.